Neuro oncology News and Research

RSS

Zale Lipshy University Hospital receives 2013 Press Ganey Beacon of Excellence Award

Zale Lipshy University Hospital at UT Southwestern Medical Center received the 2013 Press Ganey Beacon of Excellence Award for patient satisfaction, one of only three academic medical centers in the nation and one of 26 health care facilities selected nationally to receive that distinction.

21 Nov 2013

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Researchers from the University of Missouri School of Medicine have found that a new protocol that uses preventive blood-thinning medication in the treatment of patients with traumatic brain injuries reduces the risk of patients developing life-threatening blood clots without increasing the risk of bleeding inside the brain.

19 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

Investigators find potential new target for treatment of low-grade gliomas

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

7 Nov 2013

ESMO recognises oncologists with prestigious awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.

5 Sep 2013

New data analyzing technique via MR imaging identify tumors' response to anti-angiogenesis therapy

A new way of analyzing data acquired in MR imaging appears to be able to identify whether or not tumors are responding to anti-angiogenesis therapy, information that can help physicians determine the most appropriate treatments and discontinue ones that are ineffective.

20 Aug 2013

Phase II trial to investigate vaccine therapy combined with Avastin for patients with recurrent GBM

Northwestern Medicine- recently joined a landmark clinical trial to investigate if a vaccine made from a patient's own brain tumor is effective in slowing tumor progression and extending survival.

16 Aug 2013

Viewpoints: Disability insurance 'time bomb;' Leavitt on the lessons of Medicare Part D's rollout; Boys and eating disorders

Social Security for retirement and Medicare are the best known of the major entitlement programs with looming financial disasters. While some argue about when they will run out of money, their projected 75-year unfunded liabilities grow larger every year and now total $40 trillion, much worse thereafter. But the ticking time bomb of entitlement reform is Social Security's Disability Insurance Fund (Michael J. Boskin, 7/14).

16 Jul 2013

Orlando Health and UF health partner to expand neurosurgery program

Orlando Health and the University of Florida department of neurosurgery have partnered to expand the neurosurgery program at Orlando Health with the opening of a specialized practice, UF Health Neurosurgery — Orlando Health.

10 Jul 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Cytomegalovirus might accelerate the development of glioblastoma

A virus that infects most Americans but that usually remains dormant in the body might speed the progression of an aggressive form of brain cancer when particular genes are shut off in tumor cells, new research shows.

1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Radiotherapy: First choice treatment for low-grade glioma

In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.

30 May 2013

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.

17 May 2013

John Theurer to host 9th annual neuro-oncology symposium on May 17

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

10 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

NeuroBlate Thermal Therapy System safe for treating recurrent glioblastoma, study shows

The first-in-human study of the NeuroBlate Thermal Therapy System finds that it appears to provide a new, safe and minimally invasive procedure for treating recurrent glioblastoma, a malignant type of brain tumor.

6 Apr 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013